View ValuationBotanix Pharmaceuticals 将来の成長Future 基準チェック /26Botanix Pharmaceuticals利益と収益がそれぞれ年間76.3%と71%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-10.3% 87.2%なると予測されています。主要情報76.3%収益成長率87.22%EPS成長率Pharmaceuticals 収益成長51.1%収益成長率71.0%将来の株主資本利益率-10.29%アナリストカバレッジLow最終更新日18 Jun 2026今後の成長に関する最新情報Breakeven Date Change • May 20No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$2.05m in 2028.Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$8.50m in 2028.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • May 20No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$2.05m in 2028.Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$8.50m in 2028.Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 20Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,341,646 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 68,991,667 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Optionsお知らせ • Apr 10Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 247,994,473 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 406,698,517 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,333,333 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Feb 17+ 1 more updateBotanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 83,333,334 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached OptionsBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.047 loss per share (vs AU$0.009 loss in FY 2024)Full year 2025 results: AU$0.047 loss per share (further deteriorated from AU$0.009 loss in FY 2024). Net loss: AU$86.4m (loss widened AU$72.5m from FY 2024). Products in clinical trials Phase III: 2 Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Pharmaceuticals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.お知らせ • Aug 30Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australiaお知らせ • Aug 25Botanix Pharmaceuticals Limited Appoints Dr. Patricia Walker to the Board, Effective August 25, 2025Botanix Pharmaceuticals Limited appointed Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies. Her impactful thought leadership in dermatology is readily apparent with over 60 publications in medical and scientific journals and an outstanding number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours. She brings a wealth of knowledge in drug development for key dermatology products, including Tazorac®, Botox Cosmetic, Juvéderm®, Hylaform®, Captique®, Lap-Band®, Inamed Silicone gel-filled breast implants, and Kybella from her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix's lead product, SofdraTM (sofpironium) topical gel, 12.45% from a preclinical asset to Phase 3 prior to its acquisition by Botanix. Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, which continues to work with prominent dermatology pharmaceutical companies.Dr Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a prestigious research fellowship at the National Institute of Health's Dermatology Branch. Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine. Dr Walker has shown a great passion for the oversight of research and new product development all stages from discovery to global market approvals. She is also experienced in securing corporate financing, product licenses, joint development efforts and initial public offerings.Board Change • Aug 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 10Botanix Pharmaceuticals Limited announced that it expects to receive AUD 48 million in funding from Kreos Capital VII (Uk) LimitedBotanix Pharmaceuticals Limited announced that it has entered into a documentation with Kreos Capital VII (UK) Limited and its related entity Kreos Capital for a loan facility of A$48 million on June 10, 2025. The Facility provides for an initial tranche of ~A$31 million, available upon closing and anticipated to be drawn down today (Tranche A) and a further ~A$15.5 million (Tranche B) available to be drawn down up to and including 1 October 2026 subject to draw down conditions. The company will issue warrants to acquire shares each with an exercise price of A$0.33 and with an expiry date five years from the date of issue, subject to the terms of the Warrant instrument. 3,030,303 Warrants will be issued on the Tranche A drawdown of the Facility and a further 1,515,151 Warrants will be issued on satisfaction of the Tranche B drawdown conditions.お知らせ • Apr 24Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listingお知らせ • Apr 15Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct ListingBoard Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 03Botanix Pharmaceuticals Limited Announces Management AppointmentsBotanix Pharmaceuticals Limited announced the appointment of Kevin Wojciechowski Head of HCP Marketing and Sales Training Mr. Wojciechowski joins the company from Avalere Health after being the Executive Director of Marketing and Sales Training at Journey Medical Corporation as well as Senior Product Marketing Manager with Medicis, amongst other senior sales training and field operations management roles with Stryker, Cephalon and J&J. Darin Van Arsdalen Director of Sales Operations Mr. Van Arsdalen comes to the company with previous experience at Incyte, Strata Skin Sciences, Encore Dermatology and Graceway Pharmaceuticals where he held senior sales operations and planning roles responsible for forecasting, field operations, alignments and data management. With more than 20 years specialised experience in sales force optimisation, Mr. Van Arsdalen will be heavily involved in development of tools for reporting around the commercialisation of Sofdra.お知らせ • Sep 10Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. AustraliaReported Earnings • Aug 31Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)Full year 2024 results: AU$0.009 loss per share (further deteriorated from AU$0.008 loss in FY 2023). Net loss: AU$13.9m (loss widened 52% from FY 2023). Revenue is forecast to grow 108% p.a. on average during the next 2 years, compared to a 42% growth forecast for the Pharmaceuticals industry in Australia. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 70% per year, which means it is well ahead of earnings.お知らせ • Jun 28Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 233,333,334 Price\Range: AUD 0.3 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct ListingNew Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$27m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$27m free cash flow). Revenue is less than US$1m (AU$437k revenue, or US$290k). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Feb 29New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$27m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$460k revenue, or US$299k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$27m). Shareholders have been diluted in the past year (32% increase in shares outstanding).お知らせ • Jan 30Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024, at 10:00 W. Australia Standard Time. Location: BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street Perth Western Australia Australia Agenda: To consider ratification of issue of Placement Shares to sophisticated and professional investors; to consider ratification of issue of Fee Options to Euroz Hartleys Limited (or its nominee(s)); and to discuss other matters.お知らせ • Nov 29Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 103,846,154 Price\Range: AUD 0.13 Discount Per Security: AUD 0.0078 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 03Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)Full year 2023 results: AU$0.008 loss per share (improved from AU$0.014 loss in FY 2022). Revenue: AU$3.77m (up 37% from FY 2022). Net loss: AU$9.15m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.お知らせ • Aug 31Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023, at 09:00 W. Australia Standard Time. Location: the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth Western Australia Australia Agenda: To consider the re-election of directors.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding). Revenue is less than US$5m (AU$6.8m revenue, or US$4.4m).お知らせ • Aug 25Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive OfficerBotanix Pharmaceuticals Limited announced that Dr. Howie McKibbon has been appointed as Chief Executive Officer of the Company, following his promotion from Chief Operating Officer. No changes to the Board have been made as a result of this appointment and the appointment is effective 24 August 2023 (Arizona time). Dr. McKibbon was also previously the Chief Commercial Officer for Botanix, and this new promotion reflects both his extensive 25 year experience in the pharmaceutical industry, as well as his development under the guidance of Executive Chairman Vince Ippolito, at Botanix and previous successful dermatology companies, such as Dermavant Sciences, Anacor and Medicis. Dr. McKibbon is based in Phoenix, Arizona, where Botanix has recently expanded its commercial operations. Prior to his roles with Botanix, Dr. McKibbon held the role of Senior Vice-President, Worldwide Commercial Operations at Dermavant Science, where he transitioned Dermavant from a subsidiary, to a fully functioning independent dermatology company and was integral in the acquisition of the product. Before that as Senior Vice President, Sales & Marketing, he built the commercial organization, led the cross-functional launch teams and sat on the clinical development team at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company acquired by Pfizer for USD 5.2 billion in 2016. Prior to Anacor, Dr. McKibbon was Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals and helped grow Medicis to be the largest independent dermatology company in the world, when it was acquired by Bausch Health for USD 2.6 billion in 2012. His background also includes cross-functional leadership positions across portfolios of neuroscience and oncology brands, at Cephalon and Wyeth Pharmaceuticals. Over the course of his career, Dr. McKibbon has launched more than 15 branded products, managed over thirty dermatology products, and played a significant role in two of the largest dermatology acquisitions with combined valuations of USD 7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University's Stetson School of Business and Economics, and a Doctor of Pharmacy from Mercer University's Southern School of Pharmacy.お知らせ • Aug 18Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023, at 09:00 W. Australia Standard Time. Location: offices of Gilbert + Tobin, Level 16, Brookfield Place Tower 2, 123 St Georges Terrace Perth Western Australia Australia Agenda: To consider ratification of issue of April Placement Shares to institutional and sophisticated investors; to ratify issue of July Placement Shares to institutional and sophisticated investors; and to ratify issue of Fee Options.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)Full year 2022 results: AU$0.013 loss per share (down from AU$0.003 loss in FY 2021). Revenue: AU$2.75m (down 60% from FY 2021). Net loss: AU$13.2m (loss widened 295% from FY 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 25First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: AU$0.007 loss per share (down from AU$0.001 profit in 1H 2021). Net loss: AU$6.51m (down AU$7.17m from profit in 1H 2021). Revenue exceeded analyst estimates by 1.9%. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$6.99m (down 7.6% from FY 2020). Net loss: AU$3.33m (loss narrowed 80% from FY 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$6.89m (down 8.9% from 1H 2020). Net income: AU$664.1k (up AU$7.66m from 1H 2020). Profit margin: 9.6% (up from net loss in 1H 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.業績と収益の成長予測CHIA:BOT - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20281463141336/30/202774-32-19-2036/30/202636-64-58-64312/31/202522-89-78-78N/A9/30/202514-88-79-78N/A6/30/20256-86-80-79N/A3/31/20254-63-59-57N/A12/31/20242-39-39-35N/A9/30/20242-27-33-22N/A6/30/20242-14-26-8N/A3/31/20241-12-26-9N/A12/31/20230-10-27-10N/A9/30/20232-10-23-11N/A6/30/20234-9-19-12N/A3/31/20235-10-20-12N/A12/31/20226-11-20-12N/A9/30/20225-12-17-12N/A6/30/20223-13-14-11N/A3/31/20221-12-8-7N/A12/31/20210-11-2-2N/A9/30/20213-7-3-3N/A6/30/20217-3-3-3N/A3/31/20217-6-6-6N/A12/31/20207-9-8-8N/A9/30/20207-13-13-13N/A6/30/20208-17-17-17N/A3/31/20208-18-21-21N/A12/31/20198-20-24-24N/A9/30/20196-18N/A-19N/A6/30/20195-17N/A-13N/A3/31/20195-15N/A-12N/A12/31/20185-13N/A-10N/A9/30/20183-12N/A-10N/A6/30/20182-11N/A-10N/A3/31/20182-8N/A-8N/A12/31/20172-6N/A-7N/A9/30/20171-5N/A-6N/A6/30/2017N/A-5N/A-5N/A12/31/2016N/A-3N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BOT今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BOT今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: BOT今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BOTの収益 ( 71% ) Australian市場 ( 6.1% ) よりも速いペースで成長すると予測されています。高い収益成長: BOTの収益 ( 71% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BOT 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 17:50終値2026/06/29 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Botanix Pharmaceuticals Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Madeleine WilliamsCanaccord GenuityJoseph PantginisH.C. Wainwright & Co.
Breakeven Date Change • May 20No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$2.05m in 2028.
Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$8.50m in 2028.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • May 20No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$2.05m in 2028.
Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Botanix Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$500.0k in 2028. New consensus forecast suggests the company will make a loss of AU$8.50m in 2028.
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 20Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 4.999999 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,341,646 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 68,991,667 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options
お知らせ • Apr 10Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 39.781579 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 247,994,473 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 406,698,517 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,333,333 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0036 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Feb 17+ 1 more updateBotanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 83,333,334 Price\Range: AUD 0.06 Discount Per Security: AUD 0.0009 Security Features: Attached Options
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Danny Sharp was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.047 loss per share (vs AU$0.009 loss in FY 2024)Full year 2025 results: AU$0.047 loss per share (further deteriorated from AU$0.009 loss in FY 2024). Net loss: AU$86.4m (loss widened AU$72.5m from FY 2024). Products in clinical trials Phase III: 2 Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Pharmaceuticals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
お知らせ • Aug 30Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 20, 2025. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia
お知らせ • Aug 25Botanix Pharmaceuticals Limited Appoints Dr. Patricia Walker to the Board, Effective August 25, 2025Botanix Pharmaceuticals Limited appointed Dr Patricia Walker, MD, PhD, to their Board of Directors, effective 25 August 2025. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies. Her impactful thought leadership in dermatology is readily apparent with over 60 publications in medical and scientific journals and an outstanding number of learned lectures to her credit. Dr Walker is the recipient of over two dozen academic and professional honours. She brings a wealth of knowledge in drug development for key dermatology products, including Tazorac®, Botox Cosmetic, Juvéderm®, Hylaform®, Captique®, Lap-Band®, Inamed Silicone gel-filled breast implants, and Kybella from her engagements with Allergan, Allergan Medical Aesthetics, Inamed, and Kythera Biopharmaceuticals. Dr Walker also led the development of Botanix's lead product, SofdraTM (sofpironium) topical gel, 12.45% from a preclinical asset to Phase 3 prior to its acquisition by Botanix. Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, which continues to work with prominent dermatology pharmaceutical companies.Dr Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a prestigious research fellowship at the National Institute of Health's Dermatology Branch. Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine. Dr Walker has shown a great passion for the oversight of research and new product development all stages from discovery to global market approvals. She is also experienced in securing corporate financing, product licenses, joint development efforts and initial public offerings.
Board Change • Aug 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 10Botanix Pharmaceuticals Limited announced that it expects to receive AUD 48 million in funding from Kreos Capital VII (Uk) LimitedBotanix Pharmaceuticals Limited announced that it has entered into a documentation with Kreos Capital VII (UK) Limited and its related entity Kreos Capital for a loan facility of A$48 million on June 10, 2025. The Facility provides for an initial tranche of ~A$31 million, available upon closing and anticipated to be drawn down today (Tranche A) and a further ~A$15.5 million (Tranche B) available to be drawn down up to and including 1 October 2026 subject to draw down conditions. The company will issue warrants to acquire shares each with an exercise price of A$0.33 and with an expiry date five years from the date of issue, subject to the terms of the Warrant instrument. 3,030,303 Warrants will be issued on the Tranche A drawdown of the Facility and a further 1,515,151 Warrants will be issued on satisfaction of the Tranche B drawdown conditions.
お知らせ • Apr 24Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 15Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 40 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 121,212,122 Price\Range: AUD 0.33 Discount Per Security: AUD 0.0165 Transaction Features: Subsequent Direct Listing
Board Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 03Botanix Pharmaceuticals Limited Announces Management AppointmentsBotanix Pharmaceuticals Limited announced the appointment of Kevin Wojciechowski Head of HCP Marketing and Sales Training Mr. Wojciechowski joins the company from Avalere Health after being the Executive Director of Marketing and Sales Training at Journey Medical Corporation as well as Senior Product Marketing Manager with Medicis, amongst other senior sales training and field operations management roles with Stryker, Cephalon and J&J. Darin Van Arsdalen Director of Sales Operations Mr. Van Arsdalen comes to the company with previous experience at Incyte, Strata Skin Sciences, Encore Dermatology and Graceway Pharmaceuticals where he held senior sales operations and planning roles responsible for forecasting, field operations, alignments and data management. With more than 20 years specialised experience in sales force optimisation, Mr. Van Arsdalen will be heavily involved in development of tools for reporting around the commercialisation of Sofdra.
お知らせ • Sep 10Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024. Location: at the offices of bdo, level 9, mia yellagonga tower 2, 5 spring street, perth, western australia. Australia
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)Full year 2024 results: AU$0.009 loss per share (further deteriorated from AU$0.008 loss in FY 2023). Net loss: AU$13.9m (loss widened 52% from FY 2023). Revenue is forecast to grow 108% p.a. on average during the next 2 years, compared to a 42% growth forecast for the Pharmaceuticals industry in Australia. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 70% per year, which means it is well ahead of earnings.
お知らせ • Jun 28Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 233,333,334 Price\Range: AUD 0.3 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$27m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$27m free cash flow). Revenue is less than US$1m (AU$437k revenue, or US$290k). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Feb 29New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$27m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$460k revenue, or US$299k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$27m). Shareholders have been diluted in the past year (32% increase in shares outstanding).
お知らせ • Jan 30Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024, at 10:00 W. Australia Standard Time. Location: BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street Perth Western Australia Australia Agenda: To consider ratification of issue of Placement Shares to sophisticated and professional investors; to consider ratification of issue of Fee Options to Euroz Hartleys Limited (or its nominee(s)); and to discuss other matters.
お知らせ • Nov 29Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 103,846,154 Price\Range: AUD 0.13 Discount Per Security: AUD 0.0078 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 03Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)Full year 2023 results: AU$0.008 loss per share (improved from AU$0.014 loss in FY 2022). Revenue: AU$3.77m (up 37% from FY 2022). Net loss: AU$9.15m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Aug 31Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023, at 09:00 W. Australia Standard Time. Location: the offices of BDO, Level 9, Mia Yellagonga Tower 2, 5 Spring Street, Perth Western Australia Australia Agenda: To consider the re-election of directors.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding). Revenue is less than US$5m (AU$6.8m revenue, or US$4.4m).
お知らせ • Aug 25Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive OfficerBotanix Pharmaceuticals Limited announced that Dr. Howie McKibbon has been appointed as Chief Executive Officer of the Company, following his promotion from Chief Operating Officer. No changes to the Board have been made as a result of this appointment and the appointment is effective 24 August 2023 (Arizona time). Dr. McKibbon was also previously the Chief Commercial Officer for Botanix, and this new promotion reflects both his extensive 25 year experience in the pharmaceutical industry, as well as his development under the guidance of Executive Chairman Vince Ippolito, at Botanix and previous successful dermatology companies, such as Dermavant Sciences, Anacor and Medicis. Dr. McKibbon is based in Phoenix, Arizona, where Botanix has recently expanded its commercial operations. Prior to his roles with Botanix, Dr. McKibbon held the role of Senior Vice-President, Worldwide Commercial Operations at Dermavant Science, where he transitioned Dermavant from a subsidiary, to a fully functioning independent dermatology company and was integral in the acquisition of the product. Before that as Senior Vice President, Sales & Marketing, he built the commercial organization, led the cross-functional launch teams and sat on the clinical development team at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company acquired by Pfizer for USD 5.2 billion in 2016. Prior to Anacor, Dr. McKibbon was Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals and helped grow Medicis to be the largest independent dermatology company in the world, when it was acquired by Bausch Health for USD 2.6 billion in 2012. His background also includes cross-functional leadership positions across portfolios of neuroscience and oncology brands, at Cephalon and Wyeth Pharmaceuticals. Over the course of his career, Dr. McKibbon has launched more than 15 branded products, managed over thirty dermatology products, and played a significant role in two of the largest dermatology acquisitions with combined valuations of USD 7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University's Stetson School of Business and Economics, and a Doctor of Pharmacy from Mercer University's Southern School of Pharmacy.
お知らせ • Aug 18Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023, at 09:00 W. Australia Standard Time. Location: offices of Gilbert + Tobin, Level 16, Brookfield Place Tower 2, 123 St Georges Terrace Perth Western Australia Australia Agenda: To consider ratification of issue of April Placement Shares to institutional and sophisticated investors; to ratify issue of July Placement Shares to institutional and sophisticated investors; and to ratify issue of Fee Options.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)Full year 2022 results: AU$0.013 loss per share (down from AU$0.003 loss in FY 2021). Revenue: AU$2.75m (down 60% from FY 2021). Net loss: AU$13.2m (loss widened 295% from FY 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Stewart Washer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 25First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: AU$0.007 loss per share (down from AU$0.001 profit in 1H 2021). Net loss: AU$6.51m (down AU$7.17m from profit in 1H 2021). Revenue exceeded analyst estimates by 1.9%. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$6.99m (down 7.6% from FY 2020). Net loss: AU$3.33m (loss narrowed 80% from FY 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$6.89m (down 8.9% from 1H 2020). Net income: AU$664.1k (up AU$7.66m from 1H 2020). Profit margin: 9.6% (up from net loss in 1H 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.